Key result
Second-line cisplatin/carboplatin therapy in ovarian cancer yielded a 43% overall response rate, which increased to 59% in patients with a cisplatin-free interval >24 months.
Why the study?
Does a second cisplatin/carboplatin-based program induce secondary responses in patients with ovarian cancer previously treated with cisplatin?
Population
82 patients with ovarian cancer previously treated with a cisplatin-based program, with a cisplatin-free…
Design
Cohort
Authors
Loading...
May guide platinum re-challenge decisions in recurrent ovarian cancer; extends observational data on treatment-free interval but warrants randomized trials.
Cohort (n=82)
No
Does a second cisplatin/carboplatin-based program induce secondary responses in patients with ovarian cancer previously treated with cisplatin?
Secondary responses to cisplatin/carboplatin-based treatment are common in ovarian cancer patients who previously responded, and the likelihood of response increases with a longer cisplatin-free interval.
Markman et al. (1991) conducted a cohort in Ovarian cancer (n=82). Second-line cisplatin/carboplatin-based therapy was evaluated on Overall response rate. Second-line cisplatin/carboplatin therapy in ovarian cancer yielded a 43% overall response rate, which increased to 59% in patients with a cisplatin-free interval >24 months.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: